Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.6700
+0.0046 (0.69%)
At close: Feb 3, 2026, 4:00 PM EST
0.7000
+0.0300 (4.48%)
After-hours: Feb 3, 2026, 5:09 PM EST
Galmed Pharmaceuticals Employees
As of December 31, 2024, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,450,000
Market Cap
3.67M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | -2 | -25.00% | 3 | 3 |
| Dec 31, 2023 | 8 | -2 | -20.00% | 3 | 5 |
| Dec 31, 2022 | 10 | -14 | -58.33% | 4 | 6 |
| Dec 31, 2021 | 24 | 0 | - | 19 | 5 |
| Dec 31, 2020 | 24 | 3 | 14.29% | 18 | 6 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Scinai Immunotherapeutics | 31 |
| Enveric Biosciences | 6 |
| Oragenics | 5 |
| CNS Pharmaceuticals | 5 |
| Artelo Biosciences | 5 |
| Matinas BioPharma Holdings | 3 |
| PMGC Holdings | 3 |
| XORTX Therapeutics | 3 |
GLMD News
- 4 days ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 2 months ago - Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PRNewsWire
- 2 months ago - Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PRNewsWire
- 2 months ago - Galmed Issues CEO Letter to Shareholders - PRNewsWire
- 2 months ago - Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 2 months ago - Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine - PRNewsWire
- 2 months ago - Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - PRNewsWire
- 5 months ago - Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - PRNewsWire